ASCOT-LLA: Extending benefits of statins to hypertensive patients

Hypertension and hypercholesterolemia frequently coexist and the interaction of these important risk factors increases cardiovascular risk considerably.¹ It is reasonable to expect that lipid lowering would reduce risk of cardiovascular events in hypertensive patients. Indeed, subgroup analyses of large randomized statin trials support this hypothesis.^2-7 However, several issues remain:

What is the blood pressure threshold for lipid-lowering therapy in hypertensive patients? In particular, will lipid lowering benefit those patients whose blood pressure is well controlled or only slightly elevated?
What is the cholesterol threshold for lipid-lowering therapy in hypertensive patients?
Hypertension is a stronger risk factor for stroke than hypercholesterolemia. Will lipid lowering provide additional reduction in stroke risk beyond that provided by blood pressure reduction?

References are listed at the end of the Data Alert.

03ASCOT.ppt

Download 03ASCOT.ppt (6 slides - 1.5MB)

Data_Alert.pdf (0.2MB)

ASCOT cardiovascular coexist Extending frequently hypercholesterolemia Hypertension hypertensive LLA statins

Related at vwbg.org

Lipids and RAS: Interactions that increase cardiovascular risk

Hypertension and hypercholesterolemia frequently coexist, and over the past decade, provocative data have emerged suggesting the existence of neurohormonal interactions between lipoproteins and the renin-angiotensin system (RAS).

ASCOT: New Insights on Aggressive Risk Factor Intervention to Prevent Major CV Events In Hypertensive Patients

Cardiovascular (CV) disease remains the leading cause of death in the United States, claiming more lives each year than the next four leading causes of death combined.

Curriculum Update #5

Interactions of lipids and RAS: Mechanisms for risk reduction

Hypertension and hypercholesterolemia, the major risk factors for atherosclerotic disease, are frequently associated.

More related